Maruho Co., Ltd.

This early-phase study tested a drug called nemolizumab in 6 people with systemic sclerosis, a rare disease that causes skin hardening and tightening. The goal was to see if the drug could reduce skin thickness over 24 weeks and to check for side effects. Results will help decide…